NH Korindo Sekuritas Indonesia
Menu
  • Our Service
    • News & Research
      • News
      • Equity Report
      • Research Fixed Income
      • Company Report
      • Outlook
      • Special Notation
    • Equity
    • Fixed Income
    • Investment Banking
      • IPO
      • E-IPO
    • Download Center
      • Download NAIK
      • Documents
    • Wealth Management
      • Mutual Funds
    • Academy
      • Stock Dictionary
      • Stock Education
  • About Us
    • Our Firm
    • Our People
    • Our Branch
    • Corporate Governance
    • FAQ
  • Contact
  • Register Now
  • ID
  • EN

Kalbe Farma Tbk (KLBF) Intact Growth Potential

  • Author
  • Recent Posts
NHKSI Research Team
NHKSI Research Team
NHKSI Research Team
Latest posts by NHKSI Research Team (see all)
  • US Stocks Jumped on Monday - March 21, 2023
  • Daily Report | 21 March 2023 - March 21, 2023
  • Weekly Report | 20 March 2023 - March 20, 2023

4.2% Sales Growth
KLBF posted the growth of 4.2% in sales from IDR4.82 trilion in 3Q16 into IDR5.02 trillion in 3Q17. The nutritional food division posting the growth of 9% and the prescription drugs division posting the growth of 8% were the bolster for the growth in sales.

Slight Growth of 1.2% in Net Profit
KLBF booked the net profit nudging up 1.2% from IDR556 billion in 3Q16 into IDR563 billion 3Q17. It succeeded to maintain the stable gross profit margin for its four business divisions. The nutritional food, prescription drugs, and consumer health divisions have the gross profit margin at the average of 56%, while the distribution & packaging division has the gross profit margin at the average of 30%.

 

Download full report HERE.

Share This Article

Related Article


Company Report | Healthy Growth Strong Results —The Best Is Yet To Come

17 Mar 2023

BBNI has delivered a strong performance throughout 2022. BBNI posted their FY22 Net Profit of IDR 18.312 T, an increase of 68% YoY.

Company Report | Maintaining Performance, Efficiency, and Strengthening Ecosystems

10 Mar 2023

BMRI recorded a fairly solid performance throughout 2022. BMRI posted their FY22 Net Profit of IDR 41,171 T, an increase of 47% YoY.

Company Report | 2023, A Time to Grow with Kupedes

06 Mar 2023

BBRI posted their FY22 net profit of IDR51.2 T, an increase of 65% YoY yet decreased by 16% QoQ due to a rise in Opex.

 

More Article

FI Business Trend

21 Mar 2023

US Stocks Jumped on Monday

US stocks jumped on Monday (20/03/23) with Dow Jones leading a 1.2% gain on the back of...

READ MORE

Daily Report

21 Mar 2023

Daily Report | 21 March 2023

US stocks jumped on Monday (20/03/23) with Dow Jones leading a 1.2% gain on the back of...

READ MORE

Report

20 Mar 2023

Weekly Report | 20 March 2023

Several banking industry turmoil plagued the US & European markets last week, ending wi...

READ MORE

Contact Us

  • Treasury Tower 51th Floor, District 8, SCBD Lot 28, Jl. Jend. Sudirman No.Kav 52-53, RT.5/RW.3, Senayan, Kebayoran Baru, South Jakarta City, Jakarta 12190
  • cso@nhsec.co.id
  • +62 21 5088 9100 (Representative Number)
    +62 21 5088 9102 (CS Number)
  • +628 118 198 111 (Official Whatsapp 1)
    +6281 67 0000 5 (Official Whatsapp 2)

Link

  • Our Firm
  • Research
  • Our People
  • Download
  • Dictionary
  • FAQ
Find us
facebook twitter instagram youtube

PT NH Korindo Sekuritas Indonesia terdaftar dan diawasi oleh Otoritas Jasa Keuangan (OJK).


Copyright 2021 NH Korindo Sekuritas. All rights reserved.